Community Outreach and Engagement (COE) has been an integral component of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) since its inception in 2007 when the Office of Outreach and Health Disparities (OOHD) was established. Its main activity is to ensure that the diverse and medically underserved populations of the DLDCCC?s catchment area benefit from innovative outreach, education, screening, and primary prevention strategies. The OOHD has grown in scope and is charged with disseminating and implementing evidence-based interventions into practice, with over $10 million in grant funding from NCI, NIH, and the Cancer Prevention and Research Institute of Texas (CPRIT). The DLDCCC?s COE is led by the OOHD, which leverages over a decade of working with academic and community partners to promote cancer awareness and prevention in the catchment area, with particular focus on medically underserved and racial/ethnic minority populations. The COE serves as a driver for the translation of research from the Research Programs and Disease Working Groups into practice in the catchment area. The COE leads the characterization of the catchment area to define the cancer burden and identify efforts to address cancer disparities. Through expanded partnerships with CHI St. Luke?s and continued partnerships with Texas Children?s Hospital, the catchment area of the DLDCCC was recently expanded to include communities of the Houston, Texas Metropolitan Statistical Area (MSA), representing a diverse population of more than 7 million individuals. In our catchment area we have identified triple negative breast, prostate in African Americans, lung, colorectal, liver, cervix, HPV- and HIV-associated malignancies, and pediatric cancers as major cancer burdens and/or cancers that disproportionally affect our catchment area population. Obesity and underutilization of cancer screening were identified as risk factors. Over the next 5 years, the COE will: (1) Continuously monitor the cancer burden and risk factors in the DLDCCC catchment area and promote the engagement of research programs to address the cancer burden and disparities in the catchment area; (2) Engage the DLDCCC catchment area populations in cancer prevention, control, survivorship outreach, education, and research to reduce cancer burden and disparities in the catchment area; and (3) Disseminate and promote integration of evidence-based interventions and findings from research DLDCCC programs, locally (e.g., in our catchment area), regionally, nationally, and globally through outreach, collaboration, and policy. This work will be accomplished with guidance from our Community Advisory Board and in close collaboration with DLDCCC Programs. It will leverage the COE?s strong expertise in developing patient- centered educational resource, methods to address cancer disparities, and implementing and disseminating multi-pronged, evidence-based interventions into practice.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-14
Application #
10025026
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2007-07-01
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Creighton, Chad J (2018) The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Rev Anticancer Ther 18:973-980
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Byrd, Tiara T; Fousek, Kristen; Pignata, Antonella et al. (2018) TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res 78:489-500
Xing, Zhen; Zhang, Yanyan; Liang, Ke et al. (2018) Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res 78:4524-4532
Chiang, Angie C A; Fowler, Stephanie W; Savjani, Ricky R et al. (2018) Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med 215:1349-1364
Szwarc, Maria M; Hai, Lan; Gibbons, William E et al. (2018) Retinoid signaling controlled by SRC-2 in decidualization revealed by transcriptomics Reproduction 156:387-395
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240
Kho, Jordan; Tian, Xiaoyu; Wong, Wing-Tak et al. (2018) Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. Am J Hum Genet 103:276-287
Liu, Yanhong; O'Brien, Jacqueline L; Ajami, Nadim J et al. (2018) Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res 8:1775-1787
Scavuzzo, Marissa A; Hill, Matthew C; Chmielowiec, Jolanta et al. (2018) Endocrine lineage biases arise in temporally distinct endocrine progenitors during pancreatic morphogenesis. Nat Commun 9:3356

Showing the most recent 10 out of 991 publications